3188 results for cancer and finances

Refine Your Search

A phase 2 expansion study of ICT01, an anti-BTN3A monoclonal antibody, in combination with azacitidine and venetoclax in patients with AML

In June , LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications."Im…

Blood Cancer Support Group (West Los Angeles) - 1st Wednesday

The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…

Blood Cancer Support Group (West Los Angeles) - 1st Wednesday

The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…

Blood Cancer Support Group (West Los Angeles) - 3rd Wednesday

The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…

Blood Cancer Support Group (West Los Angeles) - 3rd Wednesday

The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…

Identifying Prognostic Markers of Relapse in Hairy Cell Leukemia (HCL) and HCL-Variant by Profiling Mutated Blood Stem Cells and Fibrosis Pathways

This collaborative program investigates why Hairy Cell Leukemia (HCL) and its variant often relapse despite effective therapies and why fibrosis freq…

Kura Oncology logo

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

SAN DIEGO, Feb. , - Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. today announced positive topline results from , the Phase trial of ziftomenib, a …

News Release

A Phase I/II Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

SIRPα+ macrophages mediate resistance to lenalidomide in lymphoma, limiting the activity of immunotherapy for these patients. Therefore, we propose a…

know-your-enemy.jpg

Suggested Reading - Know Your Enemy: A Guidebook For Your Cancer Journey

If you or a loved one has ever been on the receiving end of this diagnosis, you know instantly that your life will never be the same. Know Your Enemy …

holiday-zoom-ash-and-michael.jpg

How to brighten holidays in the hospital for cancer patients

Cancer treatment doesn’t pause for the holidays. While the world outside is filled with lights and laughter, inside the hospital walls, patients are o…

Blog

img_6928.jpeg

Blood Cancer United Awards Recognize Individuals for Excellence in Scientific Research & Service to the Blood Cancer Community

WASHINGTON, Dec. , – Thanks to an array of scientific advances, more people who are diagnosed with blood cancer today will be cured than ever before.…

News Release

Research: Grants

Research: TAP

Epigenetic heterogeneity in age-related clonal hematopoiesis and acute myeloid leukemia

Our focus is to unravel how clonal hematopoiesis (CH) progresses to leukemia. We will investigate how epigenetic heterogeneity affects Tet2-mutant hem…

Novel targeted therapies for acute myeloid leukaemia and multiple myeloma

Outcomes for acute myeloid leukemia (AML) and multiple myeloma (MM) patients remain inadequate and new treatment options to combat resistance against …

Cotargeting oncogenic protein translation and apoptosis in acute myeloid leukemia

The focus of my research is to evaluate the efficacy of and to unravel the molecular mechanisms underpinning a novel drug combination in AML targeting…

News Article Heading

Largest Healthcare Cuts in History Passed by House and Senate

Blood Cancer United strongly condemns the bill, which puts cancer patients at risk

News Release

Chimeric antigen receptor (CAR) T-cell therapy for children and teens

Autologous CAR immunotherapy uses a person’s own immune cells (T cells) to identify and attack cancer cells.

Support Resources

Revisiting splicing factor mutations in MDS/AML – delving deep and wide

This project aims to uncover how obligatory heterozygous mutant splicing factors (SF) impact their wildtype counterparts’ functions, RNA interaction s…

Affordable Care Act (ACA) patient protections for children and teens

In plans that adhere to the ACA, you cannot be denied coverage or charged a higher premium for coverage due to any condition, including cancer.

Support Resources

Infections, low blood counts, and iron overload in young adults

Blood cancer treatment can make patients susceptible to low blood counts and infections, which may be serious and difficult to treat.

Support Resources

Understanding the clonal origin, evolution, and progression of myeloid malignancies

The overarching focus of my research is to understand the clonal origin, evolution, and progression of myeloid malignancies and biological and clinica…

Understanding and Overcoming Mechanisms of Immune Evasion after Allogeneic Transplant

Outcomes for patients with acute myelogenous leukemia who relapse after transplantation are dismal. This SCOR brings together an international group o…

Modeling and targeting leukemic transformation of human hematopoietic stem cells

Our research seeks to understand how ordered acquisition of oncogenic mutations transforms human hematopoietic stem cells into myeloid malignancies. W…

Image of book "Kelsey and Yellow Kite" Childrens book

Kelsey and the Yellow Kite: A Book for Children About Myeloma

This book has been written to help explain what myeloma is to children and teenagers. Kelsey and the Yellow Kite tells the story of a little girl call…

BAFF-ligand CAR T-cells and pre-apheresis B-cell lymphodepletion for relapsed/refractory CLL

Most CLL patients treated with CAR that target the CD19 antigen on the cell do not achieve a complete remission. CLL cells express other molecules on…

Research: Grants